Phase I/II clinical trials with donor Treg for steroid-resistant GVHD (WP2)

About the clinical trial

The TREGeneration partners

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

Paul Ehrlich Institute approves cGVHD Trial Read more

Social Media

LinkedIn TREGeneration